MedTrace Logo

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

NCT02785770 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2018-12-28

Study results available
· View outcomes & findings →

Summary

This is a study designed to ascertain the effect of PF-04447943 on QT interval in healthy adult subjects. This is conducted as part of standard drug development.

Conditions

  • Healthy

Interventions

DRUG

PF-04447943

Single oral dose of PF-04447943 administered as an extemporaneously prepared solution

DRUG

Placebo

Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution

DRUG

Moxifloxacin

Single oral dose of moxifloxacin administered as tablet

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-29
Primary Completion
2016-10-20
Completion
2016-10-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785770 on ClinicalTrials.gov